Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 9/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PYGM | P11217 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21283173 | 0.87 | CDA (0.47) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL21283066 | 0.83 | TK2 (0.37) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL14510444 | 0.83 | TK2 (0.37) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23353386 | 0.83 | TK2 (0.37) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25053728 | 0.80 | TK2 (0.35) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23906506 | 0.79 | ALDH1A1 (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL24487839 | 0.74 | PYGM (0.40) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18871272 | 0.74 | CDA (0.48) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10349593 | 0.74 | PYGM (0.40) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL31543029 | 0.74 | PYGM (0.40) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CDA 1192/4885SLC28A1 159/4885SLC28A2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.